Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357
clinicaltrials.gov
Phase
Phase 1/Phase 2
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Participants
768
clinicaltrials.gov
Lead sponsor
Boehringer Ingelheim
clinicaltrials.gov
Start date
2024-06-28
clinicaltrials.gov
Number of sites
105
clinicaltrials.gov

Summary
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab and capecitabine, with zanidatamab, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow. In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group. During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.
clinicaltrials.gov
Short title
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
clinicaltrials.gov
Official title
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)
clinicaltrials.gov

Control arm
Open label
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Phase
Phase 1/Phase 2
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2029-01-08
clinicaltrials.gov
First posted
2024-03-21
clinicaltrials.gov
Registry last updated
2026-08-06
clinicaltrials.gov
Primary completion date
2029-01-08
clinicaltrials.gov
Start date
2024-06-28
clinicaltrials.gov

Participants
768
clinicaltrials.gov
Participant count basis
Estimated
clinicaltrials.gov
Planned participants
768
clinicaltrials.gov
Protocol amendments
6
clinicaltrials.gov
Number of sites
105
clinicaltrials.gov

Data monitoring committee
No
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Boehringer Ingelheim
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT06324357
clinicaltrials.gov
ClinicalTrials.gov ID
NCT06324357
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Sequential
Purpose
Treatment
Masking
No masking
Sources for study design
clinicaltrials.gov

  1. Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period

    Timeframe: up to 21 days

    The MTD evaluation period is defined as the first 21 days of the first treatment cycle for Cohorts A, B, C, G, K, and O. The MTD evaluation period is defined as the first 28 days after the first administration of any trial medication for Cohorts M and N.

  2. Dose optimization and justification (Phase II): Objective response (OR)

    Timeframe: up to 50 months

    Objective response (OR) is defined as the best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, or treatment discontinuation as assessed by investigator review.

  1. Dose escalation (Phase Ib): Objective response (OR)

    Timeframe: up to 50 months

  2. Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) during the entire treatment period

    Timeframe: up to 50 months

  3. Dose escalation (Phase Ib): Maximum measured concentration of zongertinib (at steady state) (Cmax,(ss))

    Timeframe: up to 2 days

    For cycle 2 only.

  4. Dose escalation (Phase Ib): Area under the concentration-time curve of zongertinib over the time interval from 0 to 4h at steady state (AUC0-4h,ss)

    Timeframe: up to 2 days

    For cycle 2 only.

  5. Dose escalation (Phase Ib): Area under the concentration-time curve of zongertinib over the time interval from 0 to the last quantifiable data point at steady state (AUC0-tz,ss)

    Timeframe: up to 2 days

    For cycle 2 only.

  6. Dose optimization and justification (Phase II): Progression-free survival (PFS)

    Timeframe: up to 50 months

    PFS is defined as the time from treatment start until the earliest date of tumor progression according RECIST 1.1 based on investigator review or death from any cause, whichever occurs first.

  7. Dose optimization and justification (Phase II): Disease control (DC)

    Timeframe: up to 50 months

    DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST 1.1 from first treatment administration until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, or treatment discontinuation, as assessed by investigator review.

  8. Dose optimization and justification (Phase II): Occurrence of treatment-emergent AEs leading to zongertinib (BI 1810631) dose reduction during the on-treatment period

    Timeframe: up to 50 months

  9. Dose optimization and justification (Phase II): Maximum measured concentration (at steady state) (Cmax,(ss))

    Timeframe: up to 50 months

  10. Dose optimization and justification (Phase II): Area under the concentration-time curve over the time interval from 0 to the last quantifiable data point at steady state (AUC0-tz,ss)

    Timeframe: up to 50 months

  11. Dose optimization and justification (Phase II): Patient-reported outcome (PRO) - PRO-CTCAE

    Timeframe: up to 24 weeks

    The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library was developed to elicit symptomatic toxicity information directly from patients in cancer clinical trials. The items selected for this trial are: Mouth/throat sores, Taste changes, Decreased appetite, Nausea, Vomiting, Constipation, Diarrhoea, Shortness of breath, Cough, Rash, Skin dryness, Hair loss, Itching, Numbness \& Tingling, Fatigue, Nosebleed, Headache. PRO-CTCAE responses are scored from 0 (=none) to 4 (=very severe) (or 0/1 for absent/present).

  12. Dose optimization and justification (Phase II): Patient-reported outcome (PRO) - EORTC IL46

    Timeframe: up to 48 weeks

    The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".

  13. Dose optimization and justification (Phase II): Patient-reported outcome (PRO) - EORTC IL19

    Timeframe: up to 48 weeks

    The EORTC IL19 consists of five physical functioning scale items. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Healthy volunteers
No

  • Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the informed consent form (ICF)

  • Cohorts A to K and Cohort O: Documented Human epidermal growth factor receptor 2 overexpressing and/or amplified (HER2+), metastatic breast cancer (mBC) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma (mGEAC).

  • Cohorts L (L-ext), M, and N (metastatic colorectal cancer (mCRC)): Documented Human epidermal growth factor receptor 2 (HER2) overexpression/amplification according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) gastric cancer guidelines and according to the result of local testing.

  • For dose optimization and justification (Phase II): Patient must provide tumor tissue from locations not radiated prior to biopsy, if possible, collected through archival tissue

  • History of prior treatment lines in palliative setting:

    • For cohorts A, B, C, D, E, F, G, H, I, I-ext, J, J-ext, K and O documented investigator assessed progression after HER2-directed treatment for unresectable locally advanced or metastatic disease (For Cohorts D, H, I (I-ext), J (J-ext) - patients must have been pretreated with trastuzumab deruxtecan (T-DXd) and have progressed or have been intolerant to previous T-DXd).
    • For cohorts L, L-ext, M and N documented progression or recurrence of disease during or following their latest line of therapy. Patients must have had at least one prior line of therapy for locally advanced unresectable disease or metastatic disease (adjuvant and neoadjuvant therapy excluded) and documented disease progression or recurrence of disease during or following their latest line of therapy. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival.

  • Presence of at least one measurable lesion according to RECIST 1.1

  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

  • Adequate organ function based on laboratory values Further inclusion criteria apply.

  • Previous treatment with:

    • Any small molecule HER2 inhibitor in the palliative setting in Cohorts D, E, F, H, L, L-ext, M, and N. In Cohort D allowed in up to 15 patients in each dose level (DL).
    • T-DXd in Cohorts E and F. In Cohort E allowed in up to 15 patients in each DL.
    • trastuzumab emtansine (T-DM1) in the palliative setting in Cohort D and H. In Cohort H allowed in up to 15 patients in each DL.
    • Capecitabine in Cohort D and H. In Cohort D allowed in up to 15 patients in each DL

  • Presence of uncontrolled and/or symptomatic brain metastases, or leptomeningeal disease

  • Mean resting corrected QT interval (QT interval corrected for heart rate by Fridericia´s formula (QTcF)) >470 msec.

  • Any factors that increase the risk of QT interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, personal or family history of long QT syndrome or unexplained sudden death under 40 years-of-age.

  • Ejection fraction <50% or the lower limit of normal of the institutional standard within 28 days prior to randomization

  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening Further exclusion criteria apply.

Sources for eligibility
clinicaltrials.gov

  • The Oncology Institute of Hope and InnovationCerritos, United StatesRecruiting
  • Ellison Medical InstituteLos Angeles, United StatesNot yet recruiting
  • Valkyrie Clinical TrialsLos Angeles, United StatesRecruiting
  • University of California Los AngelesLos Angeles, United StatesRecruiting
  • University of California IrvineOrange, United StatesRecruiting
  • Sharp Memorial HospitalSan Diego, United StatesRecruiting
  • Yale University School of MedicineNew Haven, United StatesRecruiting
  • Helios CR IncLakeland, United StatesRecruiting
  • H. Lee Moffitt Cancer Center and Research InstituteTampa, United StatesRecruiting
  • Orchard Healthcare Research Inc.- SkokieSkokie, United StatesNot yet recruiting
  • Community Health NetworkIndianapolis, United StatesRecruiting
  • University of Iowa Hospitals and ClinicsIowa City, United StatesRecruiting
  • Dana-Farber Cancer InstituteBoston, United StatesRecruiting
  • University of MichiganAnn Arbor, United StatesNot yet recruiting
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesRecruiting
  • New York Cancer & Blood SpecialistsShirley, United StatesNot yet recruiting
  • Penn State Milton S. Hershey Medical CenterHershey, United StatesNot yet recruiting
  • Avera Cancer InstituteSioux Falls, United StatesRecruiting
  • Baptist Cancer Center - MemphisMemphis, United StatesRecruiting
  • SCRI Oncology PartnersNashville, United StatesRecruiting
  • Tennessee Oncology, PllcNashville, United StatesRecruiting
  • The Methodist Hospital Research InstituteHouston, United StatesRecruiting
  • The University of Texas MD Anderson Cancer CenterHouston, United StatesNot yet recruiting
  • Inova Schar Cancer InstituteFairfax, United StatesRecruiting
  • Virginia Cancer Specialists, PCFairfax, United StatesRecruiting

And 80 more, listed on the interactive page.

Sources for sites
clinicaltrials.gov

Sources for references
clinicaltrials.gov

Related records

Drugs (7)

Lead sponsors (1)

Conditions (7)

Targets (18)